![Christopher Moyses](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Moyses
Keine laufenden Positionen mehr
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Peter Nolan | M | 75 |
University of Cambridge
| 45 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Khaled Asad Nasr | M | 66 |
University of Cambridge
| 3 Jahre |
Belita S. Ong | F | - |
University of Cambridge
| 4 Jahre |
Trevor Thomas | M | - |
University of Cambridge
| 7 Jahre |
Teck Huat Tan | M | 63 |
University of Cambridge
| 4 Jahre |
James Edward Smith | M | 71 |
University of Cambridge
| 3 Jahre |
Yong Nang Tan | M | 62 |
University of Cambridge
| 4 Jahre |
Woon Kwong Seow | M | 63 |
University of Cambridge
| 4 Jahre |
Paul Young | M | 68 |
University of Cambridge
| 4 Jahre |
John Parsons | M | - |
University of Cambridge
| 1 Jahre |
Richard Morrissey | M | 68 |
University of Cambridge
| 2 Jahre |
Vijay Perapti | F | - |
University of Cambridge
| 4 Jahre |
Robert Charles Standing | M | 64 |
University of Cambridge
| 4 Jahre |
Nobuyori Kodaira | M | 75 |
University of Cambridge
| 1 Jahre |
Howard Castle-Smith | M | 65 |
University of Cambridge
| 1 Jahre |
William Graham Cooper | M | 67 |
University of Cambridge
| 1 Jahre |
Martyn King | M | - |
University of Cambridge
| 4 Jahre |
Huan Ping Low | M | 68 |
University of Cambridge
| 4 Jahre |
David Scopes | M | - |
Senexis Ltd.
![]() Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | 9 Jahre |
Dong-Gun Kim | M | 77 |
University of Cambridge
| 3 Jahre |
Steven Troop | M | - |
University of Cambridge
| 4 Jahre |
Craig Neil Duncan | M | - |
University of Cambridge
| 3 Jahre |
Joe Liebeschuetz | M | - |
University of Cambridge
| 4 Jahre |
Philip Hanson | M | 67 |
University of Cambridge
| 4 Jahre |
Andrew Broomhead | M | 63 |
University of Cambridge
| 4 Jahre |
Nigel Keith Anthony Standish Vaz | M | 67 |
University of Cambridge
| 4 Jahre |
Jem Davies | M | - |
University of Cambridge
| 3 Jahre |
Alison Beckett | F | 62 |
University of Cambridge
| 3 Jahre |
Wendy Green | F | - |
University of Cambridge
| 4 Jahre |
Rakesh Sarna | M | - |
University of Cambridge
| 3 Jahre |
Timothy Clissold | M | 64 |
University of Cambridge
| 4 Jahre |
Nai Pong Wai | M | 70 |
University of Cambridge
| 4 Jahre |
Thomas Michael Taylor | M | 68 |
University of Cambridge
| 4 Jahre |
Dame Anne Glover | M | - |
University of Cambridge
| 3 Jahre |
Najeeb Samie | M | - |
University of Cambridge
| 3 Jahre |
Howard Sheppard | M | - |
Senexis Ltd.
![]() Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
Tony H. J. Quick | M | 68 |
University of Cambridge
| 3 Jahre |
T. Paul McCubbin | M | - |
Senexis Ltd.
![]() Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
Steven C. Schroer | M | - |
University of Cambridge
| 3 Jahre |
Dennis Mulhaupt | M | - |
University of Cambridge
| 3 Jahre |
Geoffrey G. Davis | M | - |
University of Cambridge
| 3 Jahre |
Ash Banerjee | M | - |
University of Cambridge
| 4 Jahre |
Peter Foster | M | 64 |
University of Cambridge
| 4 Jahre |
Robert Robinson | M | - |
University of Cambridge
| 3 Jahre |
Joanna Mary Gordon Perry | F | 67 |
University of Cambridge
| 3 Jahre |
Keith Philip Watkins | M | - |
University of Cambridge
| 3 Jahre |
Richard Graeme Goodman | M | 66 |
University of Cambridge
| 3 Jahre |
Simon Caffyn | M | 63 |
University of Cambridge
| 4 Jahre |
Gareth Beynon | M | - |
University of Cambridge
| 3 Jahre |
Gordon Cudmore | M | - |
University of Cambridge
| 3 Jahre |
Nigel Clifford | M | 65 |
University of Cambridge
| 3 Jahre |
Richard Horlick | M | 65 |
University of Cambridge
| 1 Jahre |
Beatriz Pessoa de Araujo | F | - |
University of Cambridge
| 4 Jahre |
Kwok-Kuen Leong | M | 63 |
University of Cambridge
| 4 Jahre |
Reyaz A. Ahmad | M | - |
University of Cambridge
| 5 Jahre |
Edward Beale | M | 64 |
University of Cambridge
| 4 Jahre |
Colin Meadows White | M | 62 |
University of Cambridge
| 4 Jahre |
James Anthony McNaught-Davis | M | 65 |
University of Cambridge
| 2 Jahre |
Jonathan Treherne | M | 63 |
Senexis Ltd.
![]() Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | - |
Yiannis Petrides | M | 66 |
University of Cambridge
| 4 Jahre |
Jeremy Levin | M | 70 |
University of Cambridge
| 2 Jahre |
Yoshitaka Kitao | M | 73 |
University of Cambridge
| 4 Jahre |
Andrew Hopper | M | 71 |
University of Cambridge
| 3 Jahre |
Bennett Yankowitz | M | 68 |
University of Cambridge
| 3 Jahre |
Dominic Casserley | M | 67 |
University of Cambridge
| 4 Jahre |
Michael G. Hack | M | 67 |
University of Cambridge
| 3 Jahre |
David Checkel | M | - |
University of Cambridge
| 2 Jahre |
Dario Cossutta | M | 73 |
University of Cambridge
| 1 Jahre |
Charles Baker | M | 66 |
University of Cambridge
| 4 Jahre |
Andrew Hewson | M | 65 |
University of Cambridge
| 3 Jahre |
Jonathan Mark Huntley | M | - |
University of Cambridge
| 4 Jahre |
Andrew Unitt | M | 66 |
University of Cambridge
| 4 Jahre |
Adrian Eastwood | M | 63 |
University of Cambridge
| 4 Jahre |
Brij Mohan Tirath R. Kataria | M | - |
University of Cambridge
| 1 Jahre |
Anthony Mark Savill | M | - |
University of Cambridge
| 3 Jahre |
Mike Aspinwall | M | - |
University of Cambridge
| 4 Jahre |
Bella Ann Almeida | F | 68 |
University of Cambridge
| 3 Jahre |
Alastair K. Livesey | M | 67 |
University of Cambridge
| 4 Jahre |
Christopher Abell | M | - |
University of Cambridge
| 3 Jahre |
Andrew Galazka | M | 69 |
University of Cambridge
| 3 Jahre |
Mark Francis McAllister | M | 66 |
University of Cambridge
| 1 Jahre |
Antony D. Buss | M | - |
University of Cambridge
| 3 Jahre |
John Bailey | M | - |
University of Cambridge
| 1 Jahre |
Jonathan Charles Kingsman | M | 67 |
University of Cambridge
| 2 Jahre |
Adam C. Baker | M | - |
University of Cambridge
| 1 Jahre |
David E. Gill | M | - |
University of Cambridge
| 4 Jahre |
Peter Jackson | M | 62 |
University of Cambridge
| 4 Jahre |
Anthony Ian Walker | M | - |
University of Cambridge
| 3 Jahre |
Paul J. Carter | M | - |
University of Cambridge
| 4 Jahre |
Shoong Tat Cheng | M | 63 |
University of Cambridge
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 90 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Christopher Moyses
- Persönliches Netzwerk